|1.||Takahara, Akira: 9 articles (01/2014 - 09/2003)|
|2.||Niinuma, Kazumi: 5 articles (01/2015 - 09/2012)|
|3.||Aritomi, Shizuka: 5 articles (01/2014 - 07/2012)|
|4.||Konda, Tomoyuki: 5 articles (02/2013 - 09/2004)|
|5.||Nakao, Kazuwa: 3 articles (10/2014 - 01/2011)|
|6.||Soma, Masayoshi: 3 articles (10/2014 - 09/2010)|
|7.||Ueshima, Kenji: 3 articles (10/2014 - 01/2011)|
|8.||Kario, Kazuomi: 3 articles (02/2013 - 12/2005)|
|9.||Fujita, Toshiro: 3 articles (01/2013 - 05/2010)|
|10.||Matsuoka, Hiroaki: 3 articles (01/2013 - 01/2010)|
|1.||Hypertension (High Blood Pressure)
10/01/2007 - "Renal and vascular protective effects of cilnidipine in patients with essential hypertension."
02/01/2013 - "The Ambulatory Blood Pressure Control and Home Blood Pressure (Morning and Evening) Lowering By N-Channel Blocker Cilnidipine (ACHIEVE-ONE) trial is a large-scale clinical study on blood pressure (BP) and pulse rate (PR) in the real world with use of cilnidipine, a unique L/N-type Ca channel blocker, possessing a suppressive action on increased sympathetic activity in patients with essential hypertension. "
09/01/2012 - "The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients."
12/01/2008 - "In study II, 14 outpatients with hypertension and mild cognitive impairment (aged 79 +/- 8 years; HDSR score, 24 +/- 4) were assigned to receive cilnidipine (10-20 mg/day). "
01/01/2007 - "This study was designed to investigate effects of short-term therapy with cilnidipine on LV midwall fractional shortening (mFS) in Chinese patients with hypertension. "
01/01/2012 - "In patients with CKD, proteinuria can be decreased by switching from an L-CCB to cilnidipine, thereby improving renal function."
01/01/2012 - "After 12 months, proteinuria and heart rate were significantly decreased in the cilnidipine group, but proteinuria increased and heart rate remained unchanged in the L-CCB group. "
01/01/2009 - "Cilnidipine (3 mg/kg/ day) significantly suppressed the increase in proteinuria on day 9 and also improved the decrease in creatinine clearance without evident effect on the blood pressure. "
12/01/2007 - "This study suggests that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients when coupled with a renin-angiotensin system inhibitor."
01/01/2010 - "Our findings suggest that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients even undergoing treatment with RAS inhibitors."
07/01/2012 - "In addition, cilnidipine also suppresses the reflex tachycardia induced by its antihypertensive action in vivo. "
01/01/2004 - "Our results show that cilnidipine administered once daily is an efficient antihypertensive drug regardless of the time of dosing, without reflex tachycardia and increase in sympathetic nervous activity, and with partial inhibition of the morning activation of the sympathetic nervous system."
03/01/1997 - "Cilnidipine is thus a useful antihypertensive drug that may not cause an excessive decrease in BP or a reflex tachycardia."
01/01/2005 - "These data suggest that in hypertensive patients, a population with impaired fibrinolysis, cilnidipine may improve the fibrinolytic balance, and that cilnidipine is effective in treating hypertension without causing reflex tachycardia."
01/01/2000 - "In conclusion, cilnidipine was effective for the treatment of hypertension and did not cause reflex tachycardia in Japanese patients. "
10/01/2015 - "We investigated whether cilnidipine has neuroprotective effects on ischemic stroke in an animal model. "
12/01/2012 - "These findings suggest that cilnidipine has neuroprotective effects against hypoxia through various mechanisms, as well as a blood pressure-lowering effect, which might help to prevent ischemic stroke and reduce neuronal injury caused by ischemic stroke."
08/01/2005 - "Prophylactic effects of an N- and L-type Ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats."
06/01/2010 - "To elucidate potential additive benefit of benidipine for prevention of cardiorenal injury, we compared the cardiac and renal protective effects of equihypotensive doses of benidipine and cilnidipine in stroke-prone spontaneously hypertensive rats (SHRSP). "
04/01/2013 - "Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats."
07/01/2007 - "This study aimed to investigate the renoprotective effect on diabetic nephropathy of a novel class of Ca(2+) channel blocker, cilnidipine, that inhibits both L-type and N-type Ca(2+) channels; a conventional L-type Ca(2+) channel blocker was substituted with cilnidipine in type 2 diabetic patients with albuminuria. "
03/18/2013 - "The aim of this study was to compare the effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria. "
07/01/2006 - "The objective of this trial was to evaluate the effect of reducing albuminuria in type II diabetic patients with a combination therapy consisting of valsartan plus cilnidipine versus monotherapy with valsartan. "
06/20/2013 - "It is revealed that only nifedipine CR and cilnidipine could reduce albuminuria statistically. "
03/01/2010 - "The L/N-type calcium channel blocker, Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes."
|2.||N-Type Calcium Channels (N-Type Calcium Channel)
|5.||L-Type Calcium Channels (Dihydropyridine Receptor)
|6.||Calcium Channels (Calcium Channel)
|7.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|2.||Vagus Nerve Stimulation
|3.||Cardiopulmonary Resuscitation (CPR)